Video content above is prompted by the following:
Improving Clinician Awareness and Adoption in Community Settings
Strategies to improve molecular testing adoption in community oncology include the following:
Enhanced educational initiatives for physicians
Greater reliance on guidelines like NCCN, which provide flexibility in clinical application
Improved reimbursement policies that incentivize evidence-based care
Recognition that although biomarker-directed therapy is important, treatments that work across all patients (biomarker-agnostic) remain valuable
Recent examples of non–biomarker-directed advances include relacorilant (cortisol blocker) with nab-paclitaxel showing improved progression-free survival and overall survival in platinum-resistant ovarian cancer, and tisotumab vedotin (targeting tissue factor) in cervical cancer.
Collaboration between academic and community settings, participation in clinical research, and tissue collection for biomarker discovery remain essential for continued progress in treatment personalization.